Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 130,105 |
Reported balance
After 2026-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 27,322 · Balance 130,105 F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2: Total holdings include 102,668 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
F2: Total holdings include 102,668 shares underlying deferred restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 16:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001647971-26-000002 · form4-01052026_040119.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,105 F1 · shares: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 102,668 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000429 · form4-01032025_040109.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,783 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 50% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 75,346 shares underlying deferred restricted stock units. Read SEC document |
| May 20, 2024 Filed May 20, 2024 16:56 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCOMMON STOCK, PAR VALUE $0.001 | 10,000 | $1.89 | $18,900.00 |
DisclosureSEC source: 0001104659-24-063451 · tm2415000-1_4seq1.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,400 F1 · balance_after: Total holdings include 50,655 shares underlying deferred restricted stock and restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:51 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000908 · tm241755-6_4seq1.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 5,332 of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3 · balance_after: Total holdings include 50,655 shares underlying deferred restricted stock and restricted stock units. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001096 · tm231728-3_4seq1.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,015 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 80,000 of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer. F2 · balance_after: The total holdings include 560,000 shares of deferred restricted stock and 120,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 16:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053625 · tm2213913-10_4seq1.xml · nonDerivative · entry 5 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,015 F4 · shares: One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F5 · balance_after: The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| December 28, 2021 Filed Apr 29, 2022 16:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 5,000 | $2.45 | $12,250.00 |
DisclosureSEC source: 0001104659-22-053625 · tm2213913-10_4seq1.xml · nonDerivative · entry 4 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,015 F2 · balance_after: The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| November 16, 2021 Filed Apr 29, 2022 16:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCommon Stock, par value $0.001 | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053625 · tm2213913-10_4seq1.xml · nonDerivative · entry 3 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,015 F3 · kind: The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock. F2 · balance_after: The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| September 30, 2021 Filed Apr 29, 2022 16:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCommon Stock, par value $0.001 | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053625 · tm2213913-10_4seq1.xml · nonDerivative · entry 2 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,785 F1 · kind: The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock. F2 · balance_after: The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| August 05, 2021 Filed Apr 29, 2022 16:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | OtherCommon Stock, par value $0.001 | 305 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053625 · tm2213913-10_4seq1.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,305 F1 · kind: The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock. F2 · balance_after: The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 17:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048826 · tm219139d3_4.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,000 F1 · shares: One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 16:07 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033110 · tm2011481-3_form4.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,000 F1 · shares: One-third of the shares will vest on each January 1, 2021, 2022 and 2023, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 53,332 shares underlying deferred restricted stock units that were previously reported in Table II. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 16:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019500 · tv516221_4.xml · nonDerivative · entry 3 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 F3 · shares: One-third of the shares will vest on each January 1, 2020, 2021 and 2022, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. Read SEC document |
| January 01, 2018 Filed Apr 12, 2019 16:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019500 · tv516221_4.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,000 F1 · shares: One-third of the shares will vest on each of January 1, 2019, 2020, and 2021, subject to continued service. The reporting person elected to defer 80,000 of these shares pursuant to the issuer's Deferred Compensation Plan for Directors. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or a change in control F2 · balance_after: The total holdings include 53,332 shares underlying deferred restricted stock units that were previously reported in Table II. Read SEC document |
| July 14, 2017 Filed Jul 21, 2017 16:13 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 13,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000721 · doc4_4850.xml · derivative · entry 3 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,332 Underlying: Common Stock · 13,333 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted 50,000 shares of restricted common stock of the Issuer in July 2015 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on July 15, 2016. The Reporting Person deferred the receipt of 80% of the vested shares on July 14, 2017 and instead received 13,333 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 13,333 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. F1 · price: The Reporting Person was granted 50,000 shares of restricted common stock of the Issuer in July 2015 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on July 15, 2016. The Reporting Person deferred the receipt of 80% of the vested shares on July 14, 2017 and instead received 13,333 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 13,333 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. F2 · derivative.exercise_date: Each deferred restricted stock unit will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · derivative.expiration_date: Each deferred restricted stock unit will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
| July 14, 2017 Filed Jul 21, 2017 16:13 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Disposition to issuerCommon Stock, par value $0.001 | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000721 · doc4_4850.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,668 F1 · price: The Reporting Person was granted 50,000 shares of restricted common stock of the Issuer in July 2015 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on July 15, 2016. The Reporting Person deferred the receipt of 80% of the vested shares on July 14, 2017 and instead received 13,333 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 13,333 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 18:58 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 26,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000107 · doc4_4412.xml · derivative · entry 4 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,999 Underlying: Common Stock · 26,666 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted 100,000 shares of restricted common stock of the Issuer on January 1, 2016 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on January 1, 2017. The Reporting Person deferred the receipt of 80% of the vested shares and, on January 1, 2017, received instead 26,666 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 26,666 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. F2 · price: The Reporting Person was granted 100,000 shares of restricted common stock of the Issuer on January 1, 2016 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on January 1, 2017. The Reporting Person deferred the receipt of 80% of the vested shares and, on January 1, 2017, received instead 26,666 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 26,666 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. F3 · derivative.exercise_date: Each deferred restricted stock unit will be settled in one share of the Issuer's common stock at the time and in the matter set forth in the Plan. F3 · derivative.expiration_date: Each deferred restricted stock unit will be settled in one share of the Issuer's common stock at the time and in the matter set forth in the Plan. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 18:58 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Disposition to issuerCommon Stock, par value $0.001 | 26,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000107 · doc4_4412.xml · nonDerivative · entry 2 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,001 F2 · price: The Reporting Person was granted 100,000 shares of restricted common stock of the Issuer on January 1, 2016 for his service on the Issuer's Board of Directors. The shares vest one-third annually beginning on January 1, 2017. The Reporting Person deferred the receipt of 80% of the vested shares and, on January 1, 2017, received instead 26,666 shares of deferred restricted stock units pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). As a result, the Reporting Person is reporting the disposition of 26,666 shares of Issuer common stock in exchange for an equal number of deferred restricted stock units. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 18:58 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000107 · doc4_4412.xml · nonDerivative · entry 1 Klein Dov · CIK 0001647971 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,667 F1 · shares: One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.